Login
Communauté Vinci
Extérieur
Si votre nom d'utilisateur ne se termine pas par @vinci.be ou @student.vinci.be, utilisez le formulaire ci-dessous pour accéder à votre compte de lecteur.
Titre : | Analyse de lactivité de la nisine A sur des isolats cliniques de Staphylococcus spp |
Auteurs : | Chelsea Ushimira, Auteur ; Hector Rodriguez-Villalobos, Promoteur |
Type de document : | Travail de fin d'études |
Editeur : | Woluwe-Saint-Lambert : Haute École Léonard de Vinci, 2024 |
Index. décimale : | TFE - Biologie médicale |
Mots-clés: | Bactériocine ; Staphylococcus ; Nisine |
Résumé : | This study emphasizes the urgent need for targeting multi-resistant bacteria due to the increasing inefficacy of antibiotics. Bacteriocins, which are already used in the industry, could be a therapeutic option to explore. One such bacteriocin is nisin, which is produced by Gram-positive bacteria belonging to Lactococcus Lactis. Nisin, known for its use in the food industry, exhibits antimicrobial properties and is tested against clinical Staphylococcus spp isolates. The main objective of this study is to investigate the in vitro activity of nisin A on clinical isolates of Staphylococcus spp. The study focused on Staphylococcus spp due to the results obtained from rapid screening, which showed an effect of nisin on the MRSA ATCC 43 300 strain. Clinical isolates of Staphylococcus spp were selected for further study. The study used the micro-dilution technique to determine the minimum inhibitory concentration (MIC) values of three antibiotics for different clinical strains. It was observed that all strains treated with nisin A in combination with amikacin showed a fractional inhibitory concentration (FIC) index indicating synergy. For most strains treated with nisin A in combination with cefoxitin, the FIC index indicated additivity, synergy, or indifference. Significant decreases in MIC values were observed for both nisin A and amikacin, as well as nisin A and cefoxitin, compared to strains without bacteriocin. The study includes in vivo evaluation using Galleria mellonella larvae as an animal model. The larvae were infected with a highly virulent MRSA strain and treated with nisin A. The results showed a reduction in larval survival in the infected groups compared to the non-infected group. However, is it still preliminary results thus further research is needed to be explore. Overall, this study provides preliminary evidence of the antibacterial activity of nisin A against Staphylococcus spp. The results demonstrate a significant decrease in MIC values when nisin A is combined with certain antibiotics. Further research is recommended to explore broader bacterial strains, additional antibiotics, and refine in vivo assessments. The study suggests considering other bacteriocins and expanding the analysis to include more antibiotic-bacteriocin combinations and a bigger range of Staphylococcus spp strains. In conclusion, this study highlights the potential of nisin A as a therapeutic option, particularly in combination with antibiotics, for targeting multi-drug resistant bacteria. The findings show promising results in vitro. |
Disponible en ligne : | Oui |
Lieu du stage : | Cliniques Universitaires Saint-Luc |
Département du TFE : | Biologie médicale |
Documents numériques (1)
![]()
Ce document n'est visible qu'après identification
![]() TFE Adobe Acrobat PDF |